Show simple item record

dc.contributor.authorChiang, Ting-Wei Willen
dc.contributor.authorle, Sage Carlosen
dc.contributor.authorLarrieu, Delphineen
dc.contributor.authorDemir, Mukerremen
dc.contributor.authorJackson, Stephenen
dc.date.accessioned2016-04-13T08:25:28Z
dc.date.available2016-04-13T08:25:28Z
dc.date.issued2016-04-15en
dc.identifier.citationScientific Reports 2016en
dc.identifier.issn2045-2322
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/254946
dc.description.abstractThe RNA-guided Cas9 nuclease is being widely employed to engineer the genomes of various cells and organisms. Despite the efficient mutagenesis induced by Cas9, off target effects have raised concerns over the system’s specificity. Recently a “doublenicking” strategy using catalytic mutant Cas9^D10A nickase has been developed to minimise off-target effects. Here, we describe a Cas9^D10A -based screening approach that combines an All-in-One Cas9^D10A nickase vector with fluorescence-activated cell sorting enrichment followed by high-throughput genotypic and phenotypic clonal screening strategies to generate isogenic knockouts and knock-ins highly efficiently, with minimal off-target effects. We validated this approach by targeting genes for the DNA-damage response proteins MDC1, 53BP1, RIF1 and P53, plus the nuclear architecture proteins Lamin A/C, in three different human cell lines. We also efficiently obtained biallelic knock-in clones, using single-stranded oligodeoxynucleotides as homologous templates, for insertion of an EcoRI recognition site at the RIF1 locus and introduction of a point mutation at the histone H2AFX locus to abolish assembly of DDR factors at sites of DNA double-strand breaks. This versatile screening approach should facilitate research aimed at defining gene functions, modelling of cancers and other diseases underpinned by genetic factors, and exploring new therapeutic opportunities.
dc.description.sponsorshipWe thank all members of the S.P.J. laboratory for helpful discussions. We are especially grateful to Y. Galanty, R. Belotserkovskaya and J. Forment for valuable ideas and suggestions, and for critically reading the manuscript, and K. Dry for editorial assistance. In addition, we thank A. Riddell (Flow Cytometry Core Facility at the University of Cambridge Stem Cell Institute) for flow cytometry cell sorting support, and Roger Grand (University of Birmingham, Birmingham, UK) for the gift of HEK293FT cells. The Jackson laboratory is funded by Cancer Research UK program grant C6/A18796 and the European Research Council. Core infrastructure funding is provided by CRUK (C6946/A14492) and the Wellcome Trust (WT092096). S.P.J. receives his salary from the University of Cambridge, UK, supplemented by CRUK. T-W.C. is supported by a Cambridge International Scholarship. C.S. and M.D. are funded by ERC Advanced Researcher Grant DDREAM. D.L is funded by a Project Grant from the Medical Research Council, UK MR/L019116/1.
dc.languageEnglishen
dc.language.isoenen
dc.publisherNature Publishing Group
dc.rightsAttribution 4.0 International
dc.rightsAttribution 4.0 Internationalen
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectCRISPR-Cas9en
dc.subjectnickaseen
dc.subjectgenotypic screeningen
dc.subjectphenotypic screeningen
dc.subjectDNA damage responseen
dc.titleCRISPR-Cas9^D10A nickase-based genotypic and phenotypic screening to enhance genome editingen
dc.typeArticle
dc.provenance7950
dc.description.versionThis is the final version of the article. It first appeared from Nature Publishing Group via https://doi.org/10.1038/srep24356en
prism.number24356en
prism.publicationDate2016en
prism.publicationNameScientific Reportsen
prism.volume6en
dc.rioxxterms.funderCRUK
dc.rioxxterms.funderWellcome Trust
dc.rioxxterms.funderMRC
dc.rioxxterms.projectidC6/A18796
dc.rioxxterms.projectidC6946/A14492
dc.rioxxterms.projectidWT092096
dc.rioxxterms.projectidMR/L019116/1
dcterms.dateAccepted2016-03-24en
rioxxterms.versionofrecord10.1038/srep24356en
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2016-04-15en
dc.contributor.orcidLarrieu, Delphine [0000-0002-2335-9361]
dc.contributor.orcidJackson, Stephen [0000-0001-9317-7937]
dc.identifier.eissn2045-2322
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idCancer Research UK (A18796)
pubs.funder-project-idMRC (MR/L019116/1)
pubs.funder-project-idCancer Research UK (11224)
pubs.funder-project-idWellcome Trust (092096/Z/10/Z)
pubs.funder-project-idCancer Research UK (A14492)
cam.orpheus.successThu Jan 30 12:54:12 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International